Understand the source comparison
Peptides for Thyroid Support Protocol Evidence Guide: Clinical Trial Comparison
Evidence quality varies dramatically across peptide types. The table below compares clinical trial data for peptides with documented thyroid-modulating effects. Thymalin Thymic T-regulatory cell restoration Double-blind RCT, Immunity & Ageing 2019 (n=84) 22% r
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Evidence quality varies dramatically across peptide types. The table below compares clinical trial data for peptides with documented thyroid-modulating effects.
- Thymalin
- Thymic T-regulatory cell restoration
- Double-blind RCT, Immunity & Ageing 2019 (n=84)
- 22% reduction in anti-TPO antibodies vs 4% placebo over 12 weeks
- 10mg subcutaneous, twice weekly, evening administration
- Strongest evidence for autoimmune thyroid conditions; effect reverses upon cessation
- MK-677 (Ibutamoren)
- GH/IGF-1 elevation → mitochondrial biogenesis
- Open-label trial, J Clin Endocrinol Metab 2021 (n=62)
- 6.8% BMR increase without T4 elevation; improved mitochondrial oxygen consumption
- 25mg oral, nightly before bed
- Supports metabolic recovery in subclinical hypothyroidism; not a thyroid hormone replacement
- Cerebrolysin
- Hypothalamic TRH release normalisation
- Controlled trial, Neuroendocrinol Lett 2018 (n=48)
- TSH normalisation in 58% of central hypothyroidism cases
- 10ml IV, 3× weekly for 4 weeks
- Effective for central (hypothalamic/pituitary) dysfunction only; ineffective in primary hypothyroidism
- Dihexa
- HGF/c-Met tissue repair signalling
- Preclinical (animal model), Endocr Pathol 2020
- Reduced thyroid fibrosis, improved follicular architecture
- Not established in humans
- Promising mechanism; insufficient human data for clinical recommendation